natgillin/translations-raw huggingface dataset:
The isolated monoclonal antibody of claim 1, which specifically binds to tumor initiating cells. The isolated monoclonal antibody of claim 1, which is an internalizing antibody. The isolated monoclonal antibody of claim 1, which is selected from the group consisting of a primatized antibody, multispecific antibody, bispecific antibody, monovalent antibody, multivalent antibody, anti-idiotypic antibody, diabody, Fab fragment, F(ab′)2 fragment, Fv fragment, and ScFv fragment; or an immunoreactive fragment thereof. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je protutijelo anti-DLL3 odabrano iz skupine koju čine monoklonalno protutijelo, kimerno protutijelo, CDR-cijepljeno protutijelo, humanizirano protutijelo, ljudsko protutijelo, primatizirano protutijelo, multispecifično protutijelo, bispecifično protutijelo, monovalentno protutijelo, multivalentno protutijelo, diabody, Fab-fragment, F(ab'),-fragment, Fv- fragment i ScFv-fragment; ili njegov imunoreaktivni fragment koji se specifično veže na epitop unutar DSL-domene od DLI.3-proteina prema SEQ ID NO:3 ili SEQ ID NO:4.
hydroxy, C1-6 alkyl or -ORc {Rc is C1-6 alkyl optionally substituted by 1, 2 or 3 substituents selected from the group consisting of the following (a) to (f); 
(4) -OR* [R*je C,s alkil, koji može biti supstituiran s 1, 2 ili 3 supstituenta, koje se bira iz skupine koju čine sljedeći (a) do (1);
obtaining squalene that has been purified from a yeast that produces a high yield of squalene during culture, wherein the yeast is grown in a controlled medium free from animal-origin products; and (b) combining the squalene of step (a) with an aqueous component to form the oil-in-water emulsion adjuvant. 
Postupak za dobivanje adjuvanta emulzija ulja u vodi, naznačen time da sadrži korake: dobivanje skvalena koji je pročišćen od kvasca koji daje visok prinos skvalena tijekom kultivacije, pri čemu je kvasac uzgojen u kontroliranom mediju bez proizvoda životinjskog podrijetla; te
A method of assembling an assembly for administering multiple doses of a component, comprising the steps of: 
Postupak sklapanja sklopa za davanje više doza sastojka, naznačen time, da sadrži stupnjeve:
The use of a combination of a corticosteroid and a B2 kinin receptor antagonist according to claim 1, for the preparation of a medicament for the prevention and therapy of respiratory tract inflammation of the dermatological and ophthalmological affections, either allergic or not, chronic or acute, particularly asthma, rhinitis, obstructive chronic bronchopathy, burn dermatitis (by heat or sun), dermatitis or eczema by exposure to allergenic or irritating substances, atopic dermatitis, autoimmune dermatitis (psoriasis), blepharitis, conjunctivitis and blepharoconjunctivitis. 
Upotreba kombinacije kortikosteroida i antagonista kininskog B2 receptora prema patentnom zahtjevu 1, naznačena time da je za pripravu lijeka za prevenciju i terapiju upala respiratornog trakta dermatoloških 1 oftalmoloških bolesti, alergijskih ili nealergijskih, kroničnih ili akutnih, posebice sljedećih: astma, rinitis, opstruktuvna kronična bronhopatija, dermatitis od opeklina (sunca ili topline), dermatitis ili ekcem zbog izlaganja alargenima ili tvarima koje zrače, atopični dermatitis, autoimuni dermatitis (psorijaza), blefaritis, konjunktivitis i befarokonjuktivitis.
The corresponding literature description is hereby introduced as a reference and is deemed to be part of the disclosure. 
Odgovarajući opis iz literature se ovime uvodi kao referenca i vrijedi kao dio otkrića.
A compound for use as a medicament, the compound represented by formula (III): wherein 
Spoj za uporabu kao lijek, te je spoj prikazan sa formulom (III): [image] naznačen time da X je CH ili N;
The pharmaceutical composition according to claim 1, in which said thiazolidin-4-one derivatives is a (Z,Z)-isomer. The pharmaceutical composition of claim 1, further comprising one or more immunosuppressant compounds. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da spomenuti derivati tiazolidin-4-ona su (Z,Z)-izomeri prema Općoj formuli (I) u zahtjevu 1.
selecting the test antibody if its presence correlates with decreased binding of the a2 or a2B1 integrin to the antibody comprising the VL region of SEQ ID NO:19 and the VH region of SEQ ID NO:21. 
odabir testnog protutijela ako se njegova prisutnost podudara sa smanjenjem vezanja a2 ili a2B1 integrina za protutijelo koje ima VL regiju iz SEQ ID NO:19 i VH regiju iz SEQ ID NO:21.
reacting a compound of formula (II): 
(a) reakciju spoja formule (ID):
The closure and plunger of the latter two aspects of this invention may be constructed in the manner described respectively in WO-A-04/08317, WO-A-02/064439 and WO-A-03/0287785, and the elastomer material of this invention may be used as the fusible material thereof. 
Zatvarač i klip od ova dva posljednja aspekta ovog izuma mogu biti izvedeni na način kako je opisano u WO-A-04/08317, WO-A-02/064439, odnosno WO-A-03/0287785, a elastomerni materijal koji je opisan u ovom izumu može se kod njih koristiti kao materijal koji se može lijepiti.
A compound of the formula for use in a method of treating renal/kidney disease (RKD) in a subject. 
Spoj formule naznačen time što je namijenjen upotrebi u postupku liječenja bubrežne bolesti/bolesti bubrega (RKD) kod subjekta.
an insulin secretagogue, for use in a method of preventing or treating diabetes mellitus, diseases associated with diabetes mellitus, or complications of diabetes mellitus, wherein (A) and (B) are administered to a patient in need either simultaneously or separately. 
metformina naznačena time da je za uporabu u postupku prevencije ili liječenja dijabetes melitusa, bolesti povezanih sa dijabetes melitusom, ili komplikacijama dijabetes melitusa, pri čemu se (A) i (B) daju pacijentu kojemu je to potrebno bilo istovremeno ili odvojeno.
A device for measuring the temperature of a strand-like material to be heated to a target temperature, comprising: 
Uređaj za mjerenje temperature predmeta u obliku strune koji treba zagrijati do ciljane temperature, naznačen time što ima:
The process according to claim 7 wherein the virus is a flavivirus preferably selected among Dengue virus, Japanese encephalitis virus and West Nile virus. 
flavivirus poželjno izabran između Dengue virusa, virusa japanskog encefalitisa i virusa zapadnog Nila.
The method according to any one of claims 1 to 3, wherein the normal non-cancerous cells are obtained from the cancer patient. 
Individualizirano cjepivo protiv raka za uporabu prema patentnom zahtjevu 3, naznačeno time, što su stanice raka cirkulirajuće tumorske stanice.
The process of claim 1, wherein said second solvent is selected from the group consisting of methanol, ethanol, propanols, and butanols, xylene, N-methylpyrrolidinone, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine metanol, etanol, propanoli i butanoli, ksilen, N-metilpirolidinon, te smjese 2 ili više njih.
The pharmaceutical composition of claim 3, wherein the pharmaceutical composition is formulated for oral, sublingual, subcutaneous, parenteral, intravenous, intranasal, topical, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal, or intraocular administration. 
Farmaceutski sastav prema zahtjevu 19, naznačen time što je farmaceutski sastav formuliran za oralnu, sublingvalnu, podkožnu, parenteralnu, intravenoznu, intranazalnu, topikalnu, transdermalnu, intraperitonealnu, intramuskularnu, intrapulmonarnu, vaginalnu, rektalnu, ili intraokularnu primjenu.
After a recovery period, implanted rats (cortical and hippocampal EEG electrodes) were recorded over a 20 min reference period. 
Nakon perioda oporavka, štakorima s implantatima (kortikalne i hipokampalne EEG elektrode) su vršena mjerenja tijekom referentnog perioda od 20 min.
The composition of claim 1, wherein the zeta potential of the particle is from about -50 mV to about -40 mV. 
Spoj sukladno zahtjevu 1, pri čemu je zeta potencijal čestice od oko -50 mV do oko -40 mv.
Combination of this compound with other ingredients resulted in the best performance, best copper fixation and the highest fungicidal effect. Co-Biocide from the Group of Quaternary Ammonium Compound. For preparation of the wood preservative solution according to the present invention a quaternary ammonium compound is used as co-biocide. 
Kombinacija ovog spoja s drugim sastojcima je rezultirala najboljom izvedbom, najboljom fiksacijom bakra i najvišim fungicidnim učinkom. d) Za pripravu otopine drvnog konzervansa prema ovom izumu, kvaterni amonijev spoj (kvat) se upotrebljava kao ko-biocid.
2-5 show the use of the vial of Fig. 1 in a filling process. 
Slike 2 - 5 prikazuju korištenje bočice iz slike 1 u postupku punjenja.
The water vehicle of claim 1, further comprising a propulsion system to reposition the water vehicle. 
Plovilo iz zahtjeva 1, kojeg nadalje čini pogonski sustav (126) za repozicioniranje plovila (100).
A method according to claim 27, wherein said cysts are incubated in a hatching container wherein at least one magnet is arranged to separate said unhatched cysts from said free swimming live food organisms. 
Uporaba prema zahtjevu 10, naznačena time što se ciste inkubiraju u spremniku za leženje gdje je barem jedan magnet smješten tako da odvaja neizlegnute ciste od živih organizama koji slobodno plivaju i služe kao hrana.
The method of claim 1, wherein said coupling and deprotecting of an amine-protected amino acid residue is defined as depicted below: wherein 
2. < Postupak u skladu s patentnim zahtjevom 1, naznačen time što je navedeno konjugiranje i uklanjanje zaštite s amino-zaštićenog aminokiselinskog ostatka definirano kao što je opisano niže:
They were then put onto glass coverslips resting in wells of a 12 well plate and covered with 2 ml of the growing media. 
Potom su stanice postavljene na stakalca smještena u bunarićima pločice sa 12 bunara i prekrivene sa 2 ml hranjivog medija.
Scyllo-inositol according to claim 1, wherein age-related macular degeneration is dry age-related macular degeneration. 
Scilo-inozitol prema zahtjevu 1, naznačen time da senilna makularna degeneracija je suhi oblik senilne makularne degeneracije.
A compound according to any of Claims 1 to 8, wherein the compound is a pharmaceutically acceptable salt of an anion chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfonate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, glycolate, or citrate. A composition comprising: 
Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je spoj farmaceutski prihvatljiva sol aniona kojeg se bira između klorida, bromida, jodida, sulfata, bisulfata, karbonata, bikarbonata, fosfata, hidrogensulfonata, p-toluensulfonata, metansulfonata, formijata, acetata, propionata, butirata, piruvata, laktata, oksalata, malonata, maleata, sukcinat, tartarata, fumarata, glikolata ili citrata.
A Programmed Cell Death 1 (PD-1) antagonist and a Death Receptor (DR) agonist for use in a method of treating cancer, wherein the DR agonist is a DR5 agonist and/or a DR4 agonist. 
PD-1 antagonista i DR5 agonista za primjenu u metodi za liječenje raka, gdje PD-1 antagonista je anti-PD-1 antitijelo ili njegov antigen-vezujući fragment, i DR5 agonista je anti-DR5 antitijelo ili njegov antigen-vezujući fragment
During evaporation of the solvent the desired product precipitated and was collected by filtration, washed with 1,2-dichloroethane and dried. 
Tijekom uparavanja otapala željeni produkt formira talog koji se sakuplja filtriranjem, ispere se sa 1,2- dikloroetanom i osuši.
The wireless communications apparatus of claim 8, characterized in that the radio link controller is further configured to start an error control timer responsive to the indication that link resources are available for transmitting the error control message. 
Uređaj za bežičnu komunikaciju (800) iz prethodnih patentnih zahtjeva 8 ili 9 karakteriziran je na način da poruka nadzora nad pogreškom obuhvaća zahtjev za porukom liste automatski ponovljenog zahtjeva (ARQ).
a fruit flavouring agent, and 
sredstvo za davanje voćne arome, i -
where R1-R13 are as defined herein; whereupon the compound of formula IA or the compound of formula IB when R12≠hydrogen is isolated as the free base or a salt such as a pharmaceutically acceptable acid addition salt thereof. 
gdje su R'-R'* kako je to ovdje definirano; nakon čega se formula IA ili IB ako je R'" # vodik, izolira kao slobodna baza ili njezina sol, kao što je to farmaceutski prihvatljiva njezina kisela dodatna sol.
A most preferable embodiment of R7 and R7a is the following groups: 
R'* je jedna od sljedećih skupina: HR P20180885 T1 ih
Table 2: Properties of the coating formulations. 
Broj objave europskog patenta:
A pharmaceutical composition according to claim 1, wherein the transmucosal penetration enhancer is a fatty acid of 5 to 30 carbon atoms, a sulphate salt of a 5 to 30 carbon fatty acid or DMSO. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je sredstvo za poboljšanje transmukozne penetracije masna kiselina s 5 do 30 atoma ugljika, sulfatna sol masne kiseline s 5 do 30 atoma ugljika ii DMSO.
The compound of Formula (1), the pharmaceutically acceptable salt thereof, or the solvate thereof of claim 1, wherein R1 is a hydrogen atom, and R2 is a hydrogen atom; a straight or branched C1-C6 alkyl group; a straight or branched C1-C5 alkoxy grop; or a straight or branched C1-C3 thioalkyl group. 
Spoj formule (I) ili njegova farmaceutski prihvatljiva sol iz patentnog zahtjeva 1, gdje R' je atom vodika, i R* je atom vodika; ravna ili razgranata C;-Cg alkil grupa; ravna ili razgranata Cj-Cs alkoksi grupa; ili ravna ili razgranata Ci-C3 tioalkil grupa.
The present invention provides a microorganism comprising a nucleic acid comprising a mutant metA allele, wherein the microorganism further comprises nucleic acid encoding an anti-VEGF antibody or an anti-VEGF antibody fragment. 
Postupak prema patentom zahtjevu 7, naznačen time, da je nukleinska kiselina koja kodira anti- VEGEF protutijelo ili fragment anti-VEGF protutijela, nukleinska kiselina koja kodira aminokiselinsku sekvencu ID BR.
The recombinant RhCMV or HCMV vector of any one of claims 1-10, or the composition of claim 11, for use in a method of inhibiting or treating HBV in a subject in need thereof. 
Rekombinantni RhCMV ili HCMV vektor prema bilo kojem od zahtjeva 1-9, ili pripravak prema zahtjevu 10, naznačen time da je za uporabu u postupku liječenja subjekta sa zaraznom bolesti, pri čemu je zarazna bolest uzrokovana virusom humane imunodeficijencije (HIV).
A biomimetic compound comprising at least two dimers of polypeptides of claim 1 or claim 2. 
Spoj biomimetika, naznačen time, da obuhvaća najmanje dva dimera od polipeptida iz zahtjeva 1 ili zahtjeva 2.
The compound or salt of claim 77 wherein said inflammatory disease of the respiratory tract concerns the upper respiratory tract. 
Spoj ili sol za upotrebu prema patentnom zahtjevu 23, naznačen time da je navedeni tumor tumor dojke.
reacting the compound of the Formula X with formic acid and formaldehyde or a polymer of formaldehyde to form a formic acid salt of ZD6474; 
reakciju spoja formule X sa mravljom kiselinom i formaldehidom ili sa polimerom formaldehida sa svrhom nastajanja soli mravlje kiseline ZD6474;
The process air feed line 3 conveys the process air into the evaporator 40, resulting in transfer of heat from the process air to the refrigerant inside the evaporator 40, thus cooling the process air. 
- < linija za uvođenje zraka za postupak (3) vodi zrak za postupak u isparivač (40), što rezultira sa prijenosom topline od zraka za postupak na rashladno sredstvo unutar isparivača (40), te tako hladi zrak za postupak;
activating at least one of the two or more subsets of thermoelectric coolers in the second plurality of thermoelectric coolers when the temperature of the chamber exceeds an upper threshold of the steady state range including the set point temperature. 
aktiviranje (1110) najmanje jednog od dva ili više TEH-podskupova od drugog mnoštva TEH, kada temperatura u komori prelazi gornju granicu raspona ravnomjernog stanja uključujući točku potrebne vrijednosti temperature.
a core comprising at least clarithromycin; 
(i) jezgru koja sadrži klaritromicin;
LDPC decoding the L1 signaling data and the de-punctured LDPC parity bits; and 
LDPC dekodiranje signalnih podataka LI 1 zatvorenih LDPC paritetnih bitova; 1
(c2) an antigen-binding site comprising an L chain CDR1, 2, and 3 amino acid sequences of SEQ ID NOs: 141, 142, and 143 (L chain CDR of L45), respectively; 
(c2) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence L-lanca CDR-područja 1, 213 od SEQID NO: 141, 142 odnosno 143 (L-lanac CDR- područja od L45);
and Z2 are each absent or alkyl; and, Z3 is absent, -NH-, -SO2- or alkyl (wherein alkyl is optionally substituted at one or more positions by halogen, hydroxy, lower alkyl, lower alkoxy, carboxy or carbonylalkoxy) and wherein the term lower aldyl means an aldyl radical of up to 4 carbon atoms. 
Zi i Z su svaki odsutan ili alkil; te Z3z je odsutan, -NH-, ili alkil (pri čemu alkil je proizvoljno supstituiran u jednom ili više položaja sa halogenom, hidroksi, nižim alkilom, nižim alkoksi, karboksi ili karbonilalkoksi) i pri čemu izraz niži alkil znači radikal alkila sa do 4 atoma ugljika.
The aqueous emulsion is filtered under vacuum and the product is extracted with ethyl acetate (2×150 ml). 
Vodenu emulziju se profiltrira pod vakuumom i proizvod se ekstrahira s etil acetatom (2 x 150 ml).
Preferred diluents include, but are not limited to, dextrose, sorbitol, sucrose, lactose, mannitol, urea, potassium chloride, sodium chloride, gelatin, starch, methyl cellulose, ethyl cellulose, propyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, silica, polyvinyl alcohol, polyvinylpyrrolidone, and magnesium stearate. 
Povoljna sredstva za razrijeđivanje uključuju, ali nisu ograničena na, dekstrozu, sorbitol, saharozu, laktozu, manitol, ureu, kalij klorid, natrij klorid, želatinu, škrob, metil celulozu, etil celulozu, propil celulozu, hidroksimetil celulozu, hidroksietil celulozu, hidroksipropil celulozu, hidroksipropil metil celulozu, silicij, polivinil alkohol, polivinilpirolidon i magnezij stearat.
(*) amount sufficient to provide to the sugar replacement composition a sweetness about equal to the sweetness of sugar. 
(*) Količina dovoljna da sastavina koja zamjenjuje šećer ima približno jednaku slatkoću kao i šećer.
The methanol was distilled out completely and to the residue, 100 ml of isopropyl alcohol was added and further stirred for 30 min at 60-65° C. Cooled to 25-30° C. The material was again stirred at 28-32° C. for 3 hrs. 
Metanol je potpuno uklonjen destilacijom a u ostatak je dodano 100 ml izopropil alkohola te je nadalje miješano tijekom 30 minuta na 60-65 *C. Ohlađeno na 25-30 *C. Materijal je ponovno miješan na 28-32?C tijekom 3 sata.
A transport unit according to any one of the previous claims, wherein each step extends in the width direction of the mineral wool plate package substantially in parallel to the side surfaces. 
Transportna jednica sukladno bilo kojem od prethodnih zahtjeva, pri čemu se svaka stuba (9a, 9b) pruža u smjeru širine pakiranja ploče mineralne vune (1) supstancijalno paralelno bočnim površinama.
This experiment also demonstrates the importance of the selection of the linkage between the carbohydrate moiety and rapamycin as, in this example, a carbonate linkage allows for the desired hydrolysis to occur whereas the carbamate linkage remains intact and little or no rapamycin is released. 
Ovaj pokus također pokazuje važnost selekcije veze između ugljikohidratne jedinice i rapamicina budući da, u ovom primjeru, karbonatna veza omogućuje željenu hidrolizu, dok karbamatna veza ostaje čitava i oslobađa se malo ili nimalo rapamicina.
The use of any of claims 19-21, together with a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteineinduced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RT-T); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Uporaba prema bilo kojem od zahtjeva 17-19, zajedno s drugim terapijskim sredstvom koje je korisno u liječenju ili prevenciji bolesti ili stanja izabranih između; emocionalna nestabilnost; pseudobulbarni afekt; autizam; neurološki poremećaji; neurodegenerativne bolesti; ozljeda mozga; poremećaji svijesti; kardiovaskularne bolesti; glaukom; tardivna diskinezija; dijabetička neuropatija; retinopatijske bolesti; bolesti ili poremećaji uzrokovani apoptozom koja je inducirana homocisteinom; bolesti ili poremećaji uzrokovani povišenim razinama homocisteina; kronična bol; intraktabilna bol; neuropatska bol; bol posredovana simpatikusom; bol povezana s disfunkcijom probavnog sustava; epileptički napadaji; tinitus; seksualna disfunkcija; intraktabilni kašalj; dermatitis; poremećaji ovisnosti; Rettov sindrom (RIT); poremećaji glasa uslijed nekontroliranog grčenja mišića larinksa; neurotoksičnost metotreksata; i umor uzrokovan rakom. .
Figure 1 .- Shows an elevation view of the flat cardboard sheet conveyor device for boxes forming machines, object of the invention. 
HR P20171634 T1 PATENTNI ZAHTJEVI Uređaj za transportiranje plosnatih kartonskih ploča u strojevima za oblikovanje kartonskih kutija, koji ima:
wherein the first target protein enrichment step is a protein precipitation step; 
gdje prva faza obogaćivanja ciljanog proteina je faza taloženja proteina;
catalytically converting syngas from said hydrogen-lean syngas stream via a Fischer-Tropsch reaction to produce hydrocarbons containing at least naphtha; 
(b) katalitičkog prevođenja sinteznog plina iz navedene struje sinteznog plina siromašne vodikom FischerTropschovom reakcijom kako bi se dobilo ugljikovodike koji u najmanju ruku sadrže naftu;
a vaccine composition comprising 1 mg of the peptide having the amino acid sequence of SEQ ID.NO:2, and 0.125 or 0.250 mg of human granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, wherein the vaccine composition is formulated for administration as three to six monthly injections, preferably as intradermal injections; and 
(1) pripravak cjepiva koji sadrži 1 mg peptida koji sadrži sekvencu amino kiseline SHQ ID. NO:2, 1 0.125 ili 0.250 mg humanog stimulirajućeg faktora kolonije granulocita/makrofaga (GM-CSF) kao adjuvanta, pri čemu je pripravak cjepiva formuliran za davanje kao tri do šest mjesečnih injekcija, poželjno kao intradermalne injekcije; te
The sclerostin-binding antibody of claim 1 having heavy chains of SEQ ID NO: 137 and light chains of SEQ ID NO: 133. 
Protutijelo za vezanje sklerostina iz patentnog zahtjeva 1, naznačeno time, da ima teške lance SEQ ID NO: 137 i lake lance SEQ ID NO: 133.
A method according to claim 4 wherein the binding of the M3 muscarinic acetylcholine receptor is useful in the treatment of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time se što bolest bira iz skupine koju čine kronična opstruktivna plućna bolest, kronični bronhitis, astma, kronična začepljenost dišnih puteva, plućna fibroza, plućni emfizem i alergijski rinitis.